Avenacy intros generic Isuprel
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched isoproterenol hydrochloride injection, which is the generic for Bausch Health’s Isuprel.
Isoproterenol Hydrochloride Injection is indicated for:
- For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.
- For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation).
- For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available.
- For bronchospasm occurring during anesthesia.
- As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cardiogenic shock.
[Read more: Avenacy releases magnesium sulfate in water for injection]
Avenacy's Isoproterenol Hydrochloride Injection is available in 0.2 mg/ml and 1 mg/5 ml 10-pack single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, Isoproterenol Hydrochloride Injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Isoproterenol Hydrochloride Injection, to wholesale partners this week. The company said it is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Isoproterenol Hydrochloride Injection had a market value of approximately $26 million for the 12 months ending in June 2023, per IQVIA.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]